摘要
对５６例初发急性髓系白血病（ＡＭＬ）细胞ＣＤ＿（３４）抗原的表达作了检测，分析了ＣＤ＿（３４）抗原表达与临床表现及化疗疗效的关系。结果显示，ＡＭＬ细胞的ＣＤ＿（３４）表达率存在很大差别，从１％～８５％；５６例ＡＭＬ中ＣＤ＿（３４）阳性表达病例为２３例，占４１．１％。ＣＤ＿（３４）抗原表达与ＦＡＢ形态学分型无关，但Ｍ＿３型的表达阳性率明显低于Ｍ＿１、Ｍ＿２型。ＣＤ＿（３４）￣＋病例组与ＣＤ＿（３４）￣－病例组在年龄、性别及初发时白细胞总数、血红蛋白浓度、血小板计数等均无明显差异；在诱导化疗疗效上，ＣＤ＿（３４）￣＋组完全缓解率为４３．５％，明显低于ＣＤ＿（３４）￣－组的７２．７％。研究结果提示，ＡＭＬ细胞在ＣＤ＿（３４）抗原的表达上存在异质性；并具有一定的预后判断价值，建议对ＣＤ＿（３４）￣＋病例施行更为有效的、可能需与ＣＤ＿（３４＿￣－病例不同的化疗。
he profile of the CD_(34) antigen expression in 56patients with acute myeloid leukemia (AML) wasdetermined and the relationship between the antigenexpression and the clinical characteristics was analysed.The results showed that the rate of CD_(34) expression inAML cells ranged from 1% to 85% , and 23 of the 56(41. 1%) patients were CD_(34) positive. No relationshipwas observed between the antigen expression and FABmorphological subtypes, but CD_(34) expreesion was muchlower in M_3 than in the other subtypes. There was littledifference in the presenting clinical characteristics ofpatients with CD_(34)￣- or CD_(34)￣+ AML. The completeremission (CR) rate of CD_(34)￣+ AML was 43. 5% , lowerthan that 72. 7% of CD_(34)￣- AML.This study indicated that AML cells wereheterogeneous in the expression of CD_(34) antigen and thatmeasuring of CD_(34) antigen would be of some value inpredicting the response of AML to chemotherapy.
出处
《中华血液学杂志》
CAS
CSCD
北大核心
1994年第7期339-341,共3页
Chinese Journal of Hematology
关键词
白血病
CD34抗原
药物疗法
Acute myeloid leukemia CD_(34) antigenChemotherapy
